相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
Stephen Salloway et al.
JAMA NEUROLOGY (2022)
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease A Truncated Randomized Phase 2b/3 Clinical Trial
Reisa Sperling et al.
JAMA NEUROLOGY (2021)
Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes
Jonathan Graff-Radford et al.
JOURNAL OF ALZHEIMERS DISEASE (2021)
Donanemab in Early Alzheimer's Disease
Mark A. Mintun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
Sarah F. Ackley et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
What the Aducanumab Approval Reveals About Alzheimer Disease Research
Jennifer J. Manly et al.
JAMA NEUROLOGY (2021)
A Shortage of Neurologists - We Must Act Now
Jennifer J. Majersik et al.
NEUROLOGY (2021)
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
Chad J. Swanson et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment
Timothy S. Anderson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
David S. Knopman et al.
NEUROLOGY (2021)
Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab
Gil D. Rabinovici
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Revisiting FDA Approval of Aducanumab
G. Caleb Alexander et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
Vincent Planche et al.
JAMA NEUROLOGY (2021)
A Shortage of Neurologists - We Must Act Now A Report From the AAN 2019 Transforming Leaders Program
Jennifer J. Majersik et al.
NEUROLOGY (2021)
2021 Alzheimer's disease facts and figures
[Anonymous]
ALZHEIMERS & DEMENTIA (2021)
Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing
Melissa J. Armstrong et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2019)
Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia
Gil D. Rabinovici et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Longitudinal analysis of dementia diagnosis and specialty care among racially diverse Medicare beneficiaries
Emmanuel Fulgence Drabo et al.
ALZHEIMERS & DEMENTIA (2019)
Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab
Ping Chiao et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
J. Scott Andrews et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2019)
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Lawrence S. Honig et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cerebral Microbleeds: Imaging and Clinical Significance
Sven Haller et al.
RADIOLOGY (2018)
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease
Leslie M. Shaw et al.
ALZHEIMERS & DEMENTIA (2018)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease (vol 537, pg 50, 2016)
Jeff Sevigny et al.
NATURE (2017)
Systematic Review of the Efficacy of Particulate Versus Nonparticulate Corticosteroids in Epidural Injections
Priyesh Mehta et al.
PM&R (2017)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
The case for rejecting the amyloid cascade hypothesis
Karl Herrup
NATURE NEUROSCIENCE (2015)
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'
Erik S. Musiek et al.
NATURE NEUROSCIENCE (2015)
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Sebastian Palmqvist et al.
NEUROLOGY (2015)
Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
Keith A. Johnson et al.
ALZHEIMERS & DEMENTIA (2013)
MR Imaging Features of Amyloid-Related Imaging Abnormalities
J. Barakos et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2013)
MEDLINE clinical queries are robust when searching in recent publishing years
Nancy L. Wilczynski et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2013)
Susceptibility-Weighted Imaging is More Reliable Than T2*-Weighted Gradient-Recalled Echo MRI for Detecting Microbleeds
Ah-Ling Cheng et al.
STROKE (2013)
Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010
Thomas G. Beach et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
分享论文
